Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
November 04 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX) announced that it will
participate at the 14th Clinical Trials on Alzheimer's Disease
Conference (CTAD 2021) as a part of the meeting’s Late-Breaking
Readout Roundtable program on Thursday, November 11, 2021, at 11:35
a.m. Eastern Time in Boston, Massachusetts. During the company’s
30-minute presentation, Cortexyme’s chief medical officer Michael
Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh,
MD, FAAN, will provide additional GAIN Trial top-line results and
analysis.
CTAD 2021 Late-Breaking Readout Roundtable Details
Title: Top-line Results from the GAIN Trial: A Phase 2/3 Study
of Atuzaginstat in Mild to Moderate Alzheimer’s Disease.
- Presenters: Michael Detke, MD, PhD, Cortexyme’s chief medical
officer and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN,
Professor of Neurology at the Alzheimer's and Memory Disorders
Division of the Barrow Neurological Institute at Dignity Health/St.
Joseph's Hospital and Medical Center.
- Authors: Michael Detke1, Marwan Sabbagh2, Mark Ryder3, Joanna
Bolger1, Dave Hennings1, Vladimir Skljarevski1, Shirin Kapur1,
Debasish Raha1, Florian Ermini1, Mai Nguyen1, Ursula Haditsch1, Kim
Perry4, Kelly Ritch5, Suzanne Hendrix6, Sam Dickson6, Hatice
Hasturk7, Sarah Horine1, Craig Mallinckrodt1, Leslie Holsinger1,
Casey Lynch1, and Stephen Dominy1.
- Access: Cortexyme’s CTAD 2021 presentation will be accessible
on Thursday, November 11, 2021, beginning at 11:35 a.m. Eastern
Time via the company’s Investor Relations website at
ir.cortexyme.com, in addition to being accessible to CTAD
registered meeting attendees in-person and on its virtual
platform.
1Cortexyme - South San Francisco, CA (USA), 2Barrow Neurological
Institute, Dignity Health/St. Joseph’s Hospital and Medical Center
- Phoenix, AZ (USA), 3UCSF - San Francisco, CA (USA), 4Innovative
Analytics - Portage, MI (USA), 5Datafy Clinical R&D - Portage,
MI (USA), 6Pentara Corporation - Millcreek, UT (USA), 7Forsyth
Institute - Cambridge, MA (USA)
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. Cortexyme’s lead
program targets a specific, infectious pathogen called P.
gingivalis found in the brain of Alzheimer’s patients and other
organs and tied to degeneration and inflammation in humans and
animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211104005314/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024